


CLAIMS

1. A compound of formula (I)



(I)

wherein:

R¹ is heteroaryl either unsubstituted or substituted by methyl, ethyl, halo or =O; and

R² is H, methyl or ethyl.

or a salt thereof.


2. A compound or a salt thereof according to claim 1 wherein R¹ is selected from the group consisting of oxazolyl, pyrazolyl, pyridyl, pyridazinyl, and pyrimidinyl; wherein the oxazolyl, pyrazolyl, pyridyl, pyridazinyl, and pyrimidinyl may be unsubstituted or substituted by methyl, ethyl, halo or =O.
3. A compound or a salt thereof according to claim 1 or claim 2 wherein R¹ is pyridyl.
4. A compound or a salt thereof according to any one of the preceding claims wherein R² is methyl.
5. A compound or a salt thereof according to claim 1 selected from the list consisting of:
- 3-(5-chloro-6-(1-(pyridin-2-yl)ethoxy)benzo[d]isoxazol-3-yl)propanoic acid;
 - 3-(5-chloro-6-(pyridin-2-ylmethoxy)benzo[d]isoxazol-3-yl)propanoic acid;
 - 3-(5-chloro-6-(1-(5-methylpyridin-2-yl)ethoxy)benzo[d]isoxazol-3-yl)propanoic acid;
 - 3-(5-chloro-6-((5-fluoropyridin-2-yl)methoxy)benzo[d]isoxazol-3-yl)propanoic acid;
 - 3-(5-chloro-6-((5-chloropyridin-2-yl)methoxy)benzo[d]isoxazol-3-yl)propanoic acid;
 - 3-(5-chloro-6-((5-methylpyridin-2-yl)methoxy)benzo[d]isoxazol-3-yl)propanoic acid;
 - 3-(5-chloro-6-(1-(oxazol-2-yl)ethoxy)benzo[d]isoxazol-3-yl)propanoic acid;
 - 3-(5-chloro-6-(1-(5-fluoropyridin-2-yl)ethoxy)benzo[d]isoxazol-3-yl)propanoic acid;
 - 3-(5-chloro-6-(pyridazin-3-ylmethoxy)benzo[d]isoxazol-3-yl)propanoic acid;
 - 3-(5-chloro-6-(1-(pyrimidin-2-yl)ethoxy)benzo[d]isoxazol-3-yl)propanoic acid;

3-(5-chloro-6-(1-(5-chloropyridin-2-yl)propoxy)benzo[d]isoxazol-3-yl)propanoic acid;
 3-(5-chloro-6-((6-methylpyridazin-3-yl)methoxy)benzo[d]isoxazol-3-yl)propanoic acid;
 3-(5-chloro-6-(1-(5-chloropyridin-2-yl)ethoxy)benzo[d]isoxazol-3-yl)propanoic acid;
 3-(5-chloro-6-(1-(6-methylpyridazin-3-yl)ethoxy)benzo[d]isoxazol-3-yl)propanoic acid;
 3-(5-chloro-6-(1-(pyridazin-3-yl)ethoxy)benzo[d]isoxazol-3-yl)propanoic acid;
 3-(5-chloro-6-(1-(5-methylpyridin-2-yl)propoxy)benzo[d]isoxazol-3-yl)propanoic acid;
 3-(5-chloro-6-(1-(pyridin-2-yl)propoxy)benzo[d]isoxazol-3-yl)propanoic acid;
 or a salt thereof.

6. A compound or a salt thereof according to claim 1 selected from the list consisting of:


3-{5-chloro-6-[1-(5-ethylpyridin-2-yl)ethoxy]-1,2-benzoxazol-3-yl}propanoic acid;
 3-{5-chloro-6-[1-(6-ethylpyridin-2-yl)ethoxy]-1,2-benzoxazol-3-yl}propanoic acid;
 3-{5-chloro-6-[(5-chloropyrimidin-2-yl)methoxy]-1,2-benzoxazol-3-yl}propanoic acid;
 3-{5-chloro-6-[(5-methylpyrimidin-2-yl)methoxy]-1,2-benzoxazol-3-yl}propanoic acid;
 3-{5-chloro-6-[1-(2-methyl-1,3-oxazol-5-yl)ethoxy]-1,2-benzoxazol-3-yl}propanoic acid;
 3-{5-chloro-6-[1-(5-chloropyrimidin-2-yl)ethoxy]-1,2-benzoxazol-3-yl}propanoic acid;
 3-{5-chloro-6-[1-(5-methylpyrimidin-2-yl)ethoxy]-1,2-benzoxazol-3-yl}propanoic acid;
 3-{5-chloro-6-[1-(4-ethyl-1,3-oxazol-2-yl)ethoxy]-1,2-benzoxazol-3-yl}propanoic acid;
 3-{5-chloro-6-[1-(pyrimidin-2-yl)propoxy]-1,2-benzoxazol-3-yl}propanoic acid;
 3-{5-chloro-6-[1-(pyridazin-3-yl)propoxy]-1,2-benzoxazol-3-yl}propanoic acid;
 3-{5-chloro-6-[1-(6-methylpyridazin-3-yl)propoxy]-1,2-benzoxazol-3-yl}propanoic acid;
 3-{5-chloro-6-[1-(5-methylpyrimidin-2-yl)propoxy]-1,2-benzoxazol-3-yl}propanoic acid;
 3-{5-chloro-6-[1-(5-chloropyrimidin-2-yl)propoxy]-1,2-benzoxazol-3-yl}propanoic acid;
 and
 3-(5-chloro-6-(1-(1-ethyl-1H-pyrazol-3-yl)ethoxy)benzo[d]isoxazol-3-yl)propanoic acid;
 or a salt thereof.

7. A compound of formula (I) or a salt thereof according to claim 1 which is (R)-3-(5-chloro-6-(1-(pyridin-2-yl)ethoxy)benzo[d]isoxazol-3-yl)propanoic acid of formula



or a salt thereof.

8. A compound of formula (I) or a salt thereof according to claim 1 which is (R)-3-(5-chloro-6-(1-(6-methylpyridazin-3-yl)ethoxy)benzo[d]isoxazol-3-yl)propanoic acid of formula




or a salt thereof.

9. The compound of claim 7 or claim 8 as the free acid.
10. A compound as defined in any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof.
11. A compound as defined in any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof, for use in therapy.
12. A compound as defined in any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof, for use in the treatment of acute pancreatitis, chronic kidney disease, acute kidney disease, acute kidney injury, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, HIV infection, amyotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress

syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

13. A compound of formula (I) or a salt thereof according to claim 1 which is (R)-3-(5-chloro-6-(1-(6-methylpyridazin-3-yl)ethoxy)benzo[d]isoxazol-3-yl)propanoic acid of formula




or a pharmaceutically acceptable salt thereof for use in the treatment of acute pancreatitis.

14. A pharmaceutical composition comprising: a) a therapeutically effective amount of a compound of formula (I) as defined in any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof; and b) a pharmaceutically acceptable excipient.
15. A pharmaceutical composition for use in the treatment of acute pancreatitis, chronic kidney disease, acute kidney disease, acute kidney injury, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, HIV infection, amyotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure which comprises a therapeutically effective amount of a compound of formula (I) as defined in any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
16. Use of a compound as defined in any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament, for the treatment of acute pancreatitis, chronic kidney disease, acute kidney disease, acute kidney injury,

other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, HIV infection, amyotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

17. Use of a compound of formula (I) or a salt thereof according to claim 1 which is (R)-3-(5-chloro-6-(1-(6-methylpyridazin-3-yl)ethoxy)benzo[d]isoxazol-3-yl)propanoic acid of formula



or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament, for the treatment of acute pancreatitis.

18. Use of a compound of formula (I) as defined in any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, in the manufacture of a medicament, for the treatment of acute pancreatitis, chronic kidney disease, acute kidney disease, acute kidney injury, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, HIV infection, amyotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.